MX2016009493A - Sistemas trasdermicos restrictivos de abuso y mal uso. - Google Patents

Sistemas trasdermicos restrictivos de abuso y mal uso.

Info

Publication number
MX2016009493A
MX2016009493A MX2016009493A MX2016009493A MX2016009493A MX 2016009493 A MX2016009493 A MX 2016009493A MX 2016009493 A MX2016009493 A MX 2016009493A MX 2016009493 A MX2016009493 A MX 2016009493A MX 2016009493 A MX2016009493 A MX 2016009493A
Authority
MX
Mexico
Prior art keywords
abuse
misuse
deterrent
patch
aversive
Prior art date
Application number
MX2016009493A
Other languages
English (en)
Other versions
MX369030B (es
Inventor
James Enscore David
Tagliaferri Frank
Paul DAMON Steven
Smith Alan
C Gaulding Jeffrey
Original Assignee
4P Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4P Therapeutics filed Critical 4P Therapeutics
Publication of MX2016009493A publication Critical patent/MX2016009493A/es
Publication of MX369030B publication Critical patent/MX369030B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/02—Adhesive bandages or dressings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F214/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a halogen
    • C08F214/18—Monomers containing fluorine
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F214/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a halogen
    • C08F214/18—Monomers containing fluorine
    • C08F214/26—Tetrafluoroethene

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Polymers & Plastics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Materials Engineering (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Addiction (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describe un parche transdérmico restrictivo de abuso y restrictivo de mal uso que comprende agentes aversivos incorporados en la capa de soporte del parche. Los agentes aversivos pueden mostrar cinética bifásica o sostenida de liberación con una porción inmediata liberada rápidamente y una porción prolongada liberada en una manera prolongada cuando se expone a un medio de disolución. La liberación prolongada del agente aversivo proporciona la restricción contra la extracción del fármaco de parches recientes y usados y sirve para impedir el mal uso accidental de los parches usados por los niños. Los sistemas de parches restrictivos de abuso y restrictivos de mal uso se pueden usar para suministro transdérmico de agentes terapéuticamente activos y particularmente aquellos fármacos que son sumamente propensos al abuso tal como opioides y analgésicos opiáceos y estimulantes.
MX2016009493A 2014-01-22 2015-01-21 Sistemas transdérmicos restrictivos de abuso y mal uso. MX369030B (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201461930090P 2014-01-22 2014-01-22
US201461930104P 2014-01-22 2014-01-22
US201462014721P 2014-06-20 2014-06-20
US201462014723P 2014-06-20 2014-06-20
US201462083620P 2014-11-24 2014-11-24
PCT/US2015/012196 WO2015112563A2 (en) 2014-01-22 2015-01-21 Abuse and misuse deterrent transdermal systems

Publications (2)

Publication Number Publication Date
MX2016009493A true MX2016009493A (es) 2017-05-09
MX369030B MX369030B (es) 2019-10-25

Family

ID=53682116

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016009493A MX369030B (es) 2014-01-22 2015-01-21 Sistemas transdérmicos restrictivos de abuso y mal uso.

Country Status (20)

Country Link
US (5) US20170007550A1 (es)
EP (1) EP3096746B1 (es)
JP (1) JP6525165B2 (es)
KR (1) KR102226652B1 (es)
CN (3) CN115475048A (es)
AU (1) AU2015209466B2 (es)
CA (1) CA2937649C (es)
CY (1) CY1121654T1 (es)
DK (1) DK3096746T3 (es)
ES (1) ES2729871T3 (es)
HR (1) HRP20191048T1 (es)
HU (1) HUE044966T2 (es)
LT (1) LT3096746T (es)
MX (1) MX369030B (es)
PL (1) PL3096746T3 (es)
PT (1) PT3096746T (es)
RS (1) RS58759B1 (es)
RU (1) RU2700926C2 (es)
SI (1) SI3096746T1 (es)
WO (1) WO2015112563A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102226652B1 (ko) * 2014-01-22 2021-03-12 4피 테라퓨틱스 남용 및 오용 저지 경피 시스템
CA2974324A1 (en) 2015-01-28 2016-08-04 Zita S. Netzel Drug delivery methods and systems
JP2018511127A (ja) 2015-03-12 2018-04-19 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 渇望入力及び支援システム
JPWO2017164084A1 (ja) * 2016-03-24 2019-02-07 株式会社 メドレックス 誤用防止特性を有する貼付製剤
US20170273974A1 (en) 2016-03-24 2017-09-28 Medrx Co., Ltd Patch preparations with misuse prevention features
WO2018129304A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
US11596779B2 (en) 2018-05-29 2023-03-07 Morningside Venture Investments Limited Drug delivery methods and systems
EP3840727A1 (en) * 2018-08-23 2021-06-30 Eric F. Bernstein Systems, devices and methods for applying anti-vegf compounds and using such compounds to treat skin conditions
CN112526037A (zh) * 2020-12-07 2021-03-19 温州市质量技术检测科学研究院 一种检测巴克球中苦精的方法
CN114668748A (zh) * 2022-05-18 2022-06-28 张钊源 渐变型透皮贴剂及其制备方法、药物方面的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990026792A (ko) * 1997-09-26 1999-04-15 김윤 디클로페낙 디에틸암모늄염을 함유한 매트릭스형 패취제제
GB0026137D0 (en) * 2000-10-25 2000-12-13 Euro Celtique Sa Transdermal dosage form
US20040126323A1 (en) * 2002-08-20 2004-07-01 Ihor Shevchuk Transdermal dosage form comprising an active agent and a salt and free-base form of an adverse agent
US20040109886A1 (en) * 2002-08-27 2004-06-10 Larry Rigby Methods and apparatus for transdermal delivery of abusable drugs with a deterrent agent
ATE551112T1 (de) * 2003-04-04 2012-04-15 Univ Texas Polyamin-/alkalisalzmischungen zur entfernung von kohlendioxid aus gasströmen
CN1780611B (zh) * 2003-04-30 2013-01-30 珀杜医药公司 包括活性剂部分以及在活性剂层远侧的逆转剂的抗改造透皮剂型
ME00276B (me) * 2003-04-30 2011-05-10 Purdue Pharma Lp Transdermalni dozni oblik otporan na promjene koje sadrže komponentu aktivnog sredstva i komponentu suprotnog sredstva na mjestu koji je ispod sloja aktivnog sredstva
US20040219195A1 (en) * 2003-04-30 2004-11-04 3M Innovative Properties Company Abuse-resistant transdermal dosage form
US20080020028A1 (en) * 2003-08-20 2008-01-24 Euro-Celtique S.A. Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent
KR20060120678A (ko) * 2003-10-30 2006-11-27 알자 코포레이션 남용될 가능성이 감소된 경피용 진통제 시스템
PT1718258E (pt) * 2004-02-23 2009-06-16 Euro Celtique Sa Dispositivo de administração transdérmica de opióides com resistência ao abuso
JP5213204B2 (ja) * 2004-03-08 2013-06-19 リンテック株式会社 粘着シートおよびその製造方法
KR100663163B1 (ko) * 2005-10-24 2007-01-02 (주)아모레퍼시픽 비스테로이드성 소염진통제를 함유하는 경피 투여 제제
WO2008024408A2 (en) * 2006-08-22 2008-02-28 Theraquest Biosciences, Inc. Pharmaceutical formulations of cannabinoids for application to the skin and method of use
WO2008133982A2 (en) * 2007-04-27 2008-11-06 Lectec Corporation Adhesive patch with aversive agent
KR101590209B1 (ko) * 2008-05-30 2016-02-01 밀란 인크. 안정화 경피 약물 전달 시스템
EP2523944A4 (en) * 2010-01-11 2013-06-19 Mithridion Inc COMPOUNDS AND COMPOSITIONS FOR IMPROVING COGNITION, METHODS OF MAKING THE SAME, AND METHODS OF TREATMENT
US20110293681A1 (en) * 2010-02-26 2011-12-01 Lectec Corporation Hand sanitizing patch having an integrally bonded antimicrobial
WO2011123866A1 (en) * 2010-04-02 2011-10-06 Alltranz Inc. Abuse-deterrent transdermal formulations of opiate agonists and agonist-antagonists
KR102226652B1 (ko) * 2014-01-22 2021-03-12 4피 테라퓨틱스 남용 및 오용 저지 경피 시스템
CN112741822A (zh) * 2019-10-30 2021-05-04 江苏集萃新型药物制剂技术研究所有限公司 一种用于皮肤或粘膜释放活性物质的透皮贴剂给药系统

Also Published As

Publication number Publication date
JP2017505312A (ja) 2017-02-16
HRP20191048T1 (hr) 2019-09-06
EP3096746B1 (en) 2019-03-13
WO2015112563A2 (en) 2015-07-30
CN106459293A (zh) 2017-02-22
EP3096746A2 (en) 2016-11-30
DK3096746T3 (da) 2019-05-20
US20220125739A1 (en) 2022-04-28
US20200113845A1 (en) 2020-04-16
PT3096746T (pt) 2019-06-17
ES2729871T3 (es) 2019-11-06
AU2015209466B2 (en) 2019-03-07
US11759431B2 (en) 2023-09-19
EP3096746A4 (en) 2017-08-23
WO2015112563A3 (en) 2015-11-19
JP6525165B2 (ja) 2019-06-05
HUE044966T2 (hu) 2019-11-28
KR20160108831A (ko) 2016-09-20
AU2015209466A1 (en) 2016-08-11
US20190076374A1 (en) 2019-03-14
RU2016133853A (ru) 2018-03-02
CA2937649C (en) 2022-11-01
LT3096746T (lt) 2019-06-10
MX369030B (es) 2019-10-25
CN115444659A (zh) 2022-12-09
PL3096746T3 (pl) 2019-09-30
RS58759B1 (sr) 2019-06-28
KR102226652B1 (ko) 2021-03-12
SI3096746T1 (sl) 2019-07-31
US20240000720A1 (en) 2024-01-04
CA2937649A1 (en) 2015-07-30
CY1121654T1 (el) 2020-07-31
US11246840B2 (en) 2022-02-15
RU2700926C2 (ru) 2019-09-24
CN115475048A (zh) 2022-12-16
US20170007550A1 (en) 2017-01-12
RU2016133853A3 (es) 2018-09-18

Similar Documents

Publication Publication Date Title
MX2016009493A (es) Sistemas trasdermicos restrictivos de abuso y mal uso.
GB2529789A (en) Transdermal Delivery system
PH12014501231A1 (en) Transdermal delivery system comprising buprenorphine
MX2023000320A (es) Metodos para modular los niveles de farmaco en plasma mediante el uso de eritrohidroxibupropion.
MX364864B (es) Microesferas o microparticulas biodegradables o bioerosionables de liberacion progresiva suspendidas en una formulacion de farmaco inyectable de formacion de deposito solidificante.
NZ704011A (en) Abuse deterrent pharmaceutical compositions for controlled release
CL2014001450A1 (es) Forma de dosis de liberacion controlada solida que comprende un analgesico opioide dispersado en un material de matriz; metodo de preparacion; uso en el tratamiento del dolor.
MX362838B (es) Composiciones farmacéuticas de liberación prolongada para disuadir el abuso de opioides que comprenden un plastómero, un elastómero y un plastificante delicuescente.
AR095441A1 (es) Formulaciones farmacéuticas resistentes a la adulteración, proceso de preparación, método
PH12015501169A1 (en) Transdermal delivery system
MX2016014622A (es) Sistemas de suministro de medicamentos y metodos de uso relacionados.
MX2015008286A (es) Composiciones multipolimericas para liberación transdermica de farmaco.
MX2016011744A (es) Soluciones de buprenorfina de liberacion sostenida.
PH12016500666A1 (en) Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
AR092820A1 (es) Sistemas y metodos para tratar una respuesta farmacodinamica adversa inducida por opioides, unidad de dosis, kit
MX2017003638A (es) Microparticulas inyectables para liberacion hiper-localizada de agentes terapeuticos.
BR112018001564A2 (pt) sistema de entrega transdérmica
AR100910A1 (es) Forma de dosificación oral de liberación sostenida que contiene morfina y naloxona
WO2012178184A3 (en) Removable protective shell for imaging agents and bioactive substances
IN2014MU01184A (es)
AR088093A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y acetato de glatiramer

Legal Events

Date Code Title Description
FG Grant or registration